{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Alanine Aminotransferase Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Aspartate Aminotransferase Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood Creatinine Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Haemoglobin Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutrophil Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Platelet Count Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Anaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperglycaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Hypocalcaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Hypokalaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypomagnesaemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyponatraemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypophosphataemia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Clinically significant laboratory abnormalities were defined as any test results which were observed beyond the clinically acceptable limits as per the discretion of investigator. Clinical laboratory tests included chemistry, hematology and urinalysis tests.","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)","id":"OG000","title":"Ixazomib+Lenalidomide+Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Safety population was defined as all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)","title":"Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Adverse Events of ≥Grade 3 Intensity","type":"PRIMARY","unitOfMeasure":"participants"}